[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"CAMC Health System\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":95},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100627024","phase-1-prospective-ir-led-sedation-feasibility-100627024",false,"NCT07443254","Prospective IR-led Sedation Feasibility","Prospective Single-Arm Feasibility Study of IR-led Deep Sedation for Interventional Radiology Procedures Traditionally Performed With Anesthesiology Support","Inclusion Criteria:\n\n* Age 18 and older\n* Planned to undergo an image-guided IR procedure for which general anesthesia would ordinarily be requested, as determined by the performing IR physician\n* Determined by the performing IR physician to be an appropriate candidate for attempted IR-led ketamine- based deep sedation, with anesthesiology available for escalation if needed\n* Ability to provide written informed consent for participation in a study involving deep sedation\n\nExclusion Criteria:\n\n* Ingestion of solid food within 6-8 hours prior to the procedure, per institutional deep sedation guidelines\n* Known allergy or hypersensitivity to ketamine, fentanyl or midazolam\n* Inability to provide informed consent or lack of decision-making capacity\n* Prisoner status\n* Uncontrolled hypertension or other condition in which ketamine-associated sympathetic stimulation would pose unacceptable risk (e.g., aortic dissection, acute myocardial infarction)\n* Pregnancy or lactation, due to contraindication to ketamine\u002Fmidazolam\n* History of schizophrenia or other psychotic disorders for which ketamine is contraindicated\n* Medical conditions that, in the judgment of the performing IR physician in consultation with anesthesiology, preclude safe administration of ketamine-based deep sedation","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This study wants to see if some interventional radiology (IR) procedures can be done without using general anesthesia. General anesthesia needs a lot of staff and equipment. It can also cause side effects. There are not enough anesthesia providers, which makes it harder to use for every procedure.\n\nThe researchers will test deep sedation with ketamine instead. They will start with 20 patients. If it works well and is safe, they may include up to 40 patients.\n\nPatients will be asked to join the study before their procedure. The anesthesia team will be told ahead of time and will be ready to help if needed. The IR team will give the deep sedation and follow all safety rules.\n\nThe main goal is to finish the procedure without stopping early or switching to general anesthesia. The study will call this successful if fewer than 10% of cases fail. The researchers will also look at patient pain, patient satisfaction, any side effects, and how long recovery takes.",[27,28,29],"Anesthesia","Sedation and Analgesia","Interventional Radiology","RECRUITING","2026-03-05",{"date":33,"type":34},"2026-03-09","ACTUAL",{"date":36,"type":34},"2026-03-02",{"date":38,"type":20},"2027-04-03",{"name":40,"class":41},"CAMC Health System","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":42},"100574875","phase-2-statin-and-beta-blocker-use-in-patients-with-decompensated-cirrhosis-100574875","NCT06764966","Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis","A Pilot Study of Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis","Inclusion Criteria:\n\n* Patients age of 18 years or older diagnosed with any form of decompensated liver disease defined as ascites, hepatic encephalopathy, or variceal bleed presenting at Charleston Area Medical Center (CAMC) Memorial Hospital or CAMC-Gastroenterology Liver Clinic\n* Currently on an non-selective beta-blockers agreeing to have their liver disease managed by CAMC-Gastroenterology Liver Clinic as an outpatient for the 12-month follow-up period.\n\nExclusion Criteria:\n\n* Any patient \\\u003C18 years of age\n* Patients with hepatocellular carcinoma\n* Patients with ongoing alcohol use (self-reported consumption of more than one alcoholic drink per week)\n* Patients exhibiting high-risk behaviors that could put them at risk for complications including IV substance use and history of medication non-adherence\n* Patients currently on statin therapy\n* Patients with a history of statin intolerance\n* Patients on the waitlist for liver transplantation\n* Patients taking medications with known drug interactions with statins\n* Patients not able to give informed consent or patients belonging to vulnerable categories as the Federal Regulations or Common Rule",{"count":51,"type":20},50,[24],"Decompensated cirrhosis (liver disease) occurs when liver function decreases to the extent that serious complications develop and can include internal bleeding, fluid buildup in the abdomen, or mental confusion. This reduced decreased liver function subsequently decreases life expectancy. There is a critical need for strategies to delay progression to decompensation and reduce the occurrence of serious complications. Currently, limited therapeutic options are available for managing decompensated liver disease, with beta-blockers (BB) being the only proven medication with significant benefits in preventing disease progression. Statins have been historically under- prescribed in cirrhosis due to concerns of liver damage. However, there is emerging evidence that statin use may be beneficial and able to lessen liver disease worsening, with studies demonstrating its safety. Thus, we aim to conduct a pilot randomized controlled trial (RCT) study of 50 subjects comparing the outcomes of decompensated cirrhotic patients receiving the statin, atorvastatin, and a non-selective beta-blocker (NSBB) versus those receiving NSBB plus placebo. Both groups will be followed for 12 months to investigate the feasibility, safety, and efficacy of combination therapy.",[55,56,57,58],"Decompensated Liver Cirrhosis","Cirrhosis","Decompensated Cirrhosis of Liver","Decompensated Cirrhosis and Ascites",[60,61,62,63,56],"Decompensated Cirrhosis","Decompensated Liver Disease","Statins","Beta-Blockers","2026-02-23",{"date":66,"type":34},"2026-02-25",{"date":68,"type":34},"2025-09-09",{"date":70,"type":20},"2027-03",{"name":40,"class":41},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":42},"100383959","phase-4-single-center-prospective-study-to-investigate-the-difference-in-the-incidence-of-contrast-induced-nephropathy-in-high-risk-patients-with-the-use-of-the-dye-vert-plus-system-100383959","NCT04279457","Single-Center Prospective Study to Investigate the Difference in the Incidence of Contrast-Induced Nephropathy in High-Risk Patients With the Use of the Dye-Vert Plus System","Dye-Vert Plus","Inclusion Criteria:\n\n* Inclusion criteria:\n\n  1. 18 years of age or older\n  2. Scheduled to undergo CAG and\u002For PCI\n  3. Baseline estimated glomerular filtration rate (eGFR) of ≥20 and ≤60 mL\u002F min\u002F1.73 m2\n  4. Serum creatinine \\> 1.5mg\u002Fdl\n  5. Obtaining a Cardiac catheterization.\n  6. HTN\u002FDiabetes\n  7. Inpatient and outpatient\n\nExclusion Criteria:\n\n* Exclusion criteria:\n\n  1. 91 years of age or older\n  2. Serum creatinine \\\u003C 1.5mg\u002Fdl\n  3. eGFR \\> 60ml\u002Fmin\n  4. Pregnancy\n  5. Dialysis\n  6. Dye Allergy","90 Years",{"count":81,"type":20},1802,[83],"PHASE4","Coronary angiography (CAG) for diagnostic or therapeutic purposes such as percutaneous coronary intervention (PCI) is one of the common procedures which require the use of intravenous contrast media. The reported incidence of contrast induced nephropathy (CIN) in high-risk patients following CAG varies from 10% to 30%. The high rate of CIN in post-PCI patients could be related either to the patient (advanced age, previous CKD, diabetes, dehydration, and concomitant use of other nephrotoxic drugs) or procedure related (intra-arterial route of administration, use of high osmolar contrast media, repeated exposure to contrast within 48 hours, volume of contrast used). Several strategies to prevent or treat CIN have been developed, including hydration, N-acetyl-cysteine, statins, ascorbic acid, bicarbonate, aminophylline, forced diuresis, renal replacement therapy, and choice of low-osmolarity or alternative agents, but one of the most obvious means is to minimize contrast volume. The DyeVert plus Contrast Reduction System, is designed to lower the amount of contrast dye the kidneys are exposed to during a procedure. Because the amount of contrast dye is precisely controlled. The purpose of this prospective study is to understand how the monitoring system of Dye-Vert Plus will impact Acute Kidney Injuries rates in high-risk patients undergoing cardiac catheterization when used in conjunction with a standardized hydration policy.",[86],"AKI (Acute Kidney Injury) Due to Trauma","2020-02-20",{"date":89,"type":34},"2020-02-24",{"date":91,"type":34},"2020-02-03",{"date":93,"type":20},"2022-02-03",{"name":40,"class":41},""]